Tweet
I have been looking at some of my human RNA-Seq data and started to notice some strange things, which brings up some potentially difficult questions. For example do aligners (e.g. tophat) take into account the probability of incorrectly mapping a given 35-bp single end given all the possible derivatives of (0,1,2) mismatches in a given genome? For example, AGG...GCT may be in the genome 100 times more than AAA...AAA? More importantly, given the random placement of reads mapping identically or pseudo-indentically, should we also consider for a given sequence the probability of incorrectly mapping the sequence because there may be 4 places in the genome with ACTG..., but 400 with ATTG... (1bp mismatch) and 4000 with ATTT... (2bp mismatch)?
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has... -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM